Venous thromboembolism with inflammatory bowel disease

Area of Science:

• Gastroenterology
• Hematology
• Vascular Medicine

Background:

• Inflammatory bowel disease (IBD) is associated with an increased incidence of venous thromboembolism (VTE).
• Approximately 50% of VTE events in IBD patients occur without identifiable acquired or genetic risk factors.
• Inflammation control is considered the primary strategy for reducing thrombotic event risk in IBD.

Purpose of the Study:

• To review the risk factors and management strategies for venous thrombosis in patients with inflammatory bowel disease.
• To evaluate the role of anticoagulation in preventing thromboembolic events in this patient population.

Main Methods:

• Literature review of studies investigating VTE in IBD.
• Analysis of risk factors, including inflammatory activity and patient-specific conditions.
• Evaluation of current guidelines and evidence regarding prophylactic anticoagulation.

Main Results:

• IBD patients exhibit a higher prevalence of VTE compared to the general population.
• A significant proportion of VTE events in IBD lack identifiable risk factors, highlighting the role of the disease itself.
• The efficacy and safety of prophylactic anticoagulation require careful consideration of individual patient profiles.

Conclusions:

• Management of inflammation is crucial for mitigating VTE risk in IBD.
• Prophylactic anticoagulation is not routinely recommended but should be considered on a case-by-case basis.
• Risk-benefit analysis, including hemorrhage risk, prior thrombotic events, surgical needs, and coagulation disorders, is essential for guiding anticoagulation decisions.